IFRX InflaRx N.V

InflaRx to Present at Upcoming Investor Conferences

JENA, Germany--(BUSINESS WIRE)--

InflaRx N.V. (Nasdaq:IFRX), the biopharmaceutical company developing new therapeutics in the terminal complement space, will present at the following conferences:

J.P. Morgan Annual Healthcare Conference

Date: January 8-11, 2018,

Presentation: Wed, 10th Jan 8:00 am PST (5:00 pm CET)

Venue: San Francisco, CA, USA

Presenter: Prof. Niels Riedemann, Chief Executive Officer of InflaRx

Arnd Christ, Chief Financial Officer of InflaRx

LEERINK Partners 7th Annual Global Healthcare Conference

Date: February 14-15, 2018

Presentation: Wed, 14th Feb 1:30 pm EST (7:30 pm CET)

Venue: New York, NY, USA

Presenter: Prof. Niels Riedemann, Chief Executive Officer of InflaRx

Live webcasts of the presentations will be provided at www.InflaRx.com through the "Events & Presentations" section on the "Investors" page. A replay of the presentations will be available from InflaRx's website following the conferences.

About InflaRx N.V.:

InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and has offices in Jena and Munich, Germany. InflaRx is listed on the NASDAQ Global Select Market in the United States under the trading symbol "IFRX."

EN
04/01/2018

Underlying

IFRXInflaRx N.V

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on InflaRx N.V

 PRESS RELEASE
Free
IFRX INFLARX N.V

InflaRx Announces Participation in the Leerink Partners Global Healthc...

InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Leerink Partners Global Healthcare Conference. Details are as follows: Leerink Partners Global Healthcare ConferenceMarch 8 - 11, 2026 in Miami, FLFireside chat on March 9 at 9:20 AM ET InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view the fir...

February 26, 2026 1 EN
 PRESS RELEASE
Free
IFRX INFLARX N.V

InflaRx Announces Participation in February Investor Conferences

InflaRx Announces Participation in February Investor Conferences JENA, Germany, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in several investor conferences in February 2026. Details are as follows: Guggenheim Securities Emerging Outlook: Biotech Summit 2026February 11 - 12, 2026 in New York, NYFireside chat on Wednesday, February 11 at 11:30 AM ET InflaRx will also conduct one-on-one investor meetings on February 11th. A link to...

January 29, 2026 1 EN
 PRESS RELEASE
Free
IFRX INFLARX N.V

InflaRx Announces Strategy Focused on Capital-Efficient Execution with...

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS)To broaden signal-finding activities for izicopan in additional I&I (inflammation and immunology) indications, InflaRx intends to conduct a PK bridging study in China in 2026 to enable expedited proof of concept studies in China and additional geographiesToward the goal of fast-tracking izicopan development across all applicable I&I indicat...

January 8, 2026 1 EN
 PRESS RELEASE
Free
IFRX INFLARX N.V

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Py...

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), subsequent post-hoc analyses suggest a positive trend in favor of vilobelimab, with signals indicating a potentially consistent treatment effectInflaRx anticipates meeting with the FDA to determine a potential development path forward in PG, which the Company anticipates would only be conducted in collaborat...

December 30, 2025 1 EN
 PRESS RELEASE
Free
IFRX INFLARX N.V

InflaRx Announces International Nonproprietary Name of “Izicopan” for ...

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904 JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the World Health Organization (WHO) has granted the international nonproprietary (generic) name (INN) of “izicopan” to the Company for its orally available C5aR inhibitor, formerly known as INF904, in accordance with the WHO's Procedure for the Selection of Recommended International Nonproprietary Names (INN) fo...

December 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch